Physician profile
David Allen
NPI 1487672986
$5,338.58
in general payments reported to CMS, 2019-2025
21 companies · $560 in 2025
The $560 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $144 · 2021: $433 · 2022: $443 · 2023: $3,030 · 2024: $543 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $1,518 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $1,518.27 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,500.00 | 2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $858.02 | 2019-2025 | |
| Abbvie INC. | $609.51 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $250.00 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $233.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $165.10 | 2022-2025 | Sotyktu |
| Pfizer INC. | $110.56 | 2019-2024 | |
| Leo Pharma INC. | $101.73 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $91.81 | 2023-2024 | Vtama |
| Krystal Biotech INC | $76.81 | 2024-2025 | Vyjuvek |
| Regeneron Healthcare Solutions, INC. | $62.23 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $56.05 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $47.91 | 2019-2021 | |
| Genentech USA, INC. | $37.71 | 2021-2024 | Erivedge, Xolair |
| Amgen INC. | $29.43 | 2023 | Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $27.11 | 2025 | Seysara |
| Journey Medical Corporation | $20.09 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.51 | 2023 | |
| Botanix Sb INC | $16.45 | 2025 | Sofdra |
| Organon LLC | $15.10 | 2025 | Vtama |
| Ucb, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.